Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.
Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in chronic kidney disease (CKD). The ex vivo study demonstrated that vonapanitase removed elastic fibres from human cephalic veins in a dose-dependent manner, as assessed by both desmosine and histological staining of elastic fibres.
The study, titled Recombinant Human Elastase Treatment of Cephalic Veins, was published in Cardiovascular Pharmacology: Open Access. Proteons Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. Dr Karen Bingham and Dr Emma Moss of Biopta were co-authors.